Details of the Drug Combinations

General Information of This Drug (ID: DMZKGPV)

• Drug Name: Gemigliptin (DMZKGPV)
• Synonyms: 911637-19-9; UNII-5DHU18M5D6; 5DHU18M5D6; (S)-1-(2-Amino-4-(2,4-bis(trifluoromethyl)-5,6-dihydropyrido[3,4-d]pyrimidin-7(8H)-yl)-4-oxobutyl)-5,5-difluoropiperidin-2-one; (S)-1-(2-amino-4-(2,4-bis(trifluoromethyl)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)-4-oxobutyl)-5,5-difluoropiperidin-2-one; Gemigliptin [INN]; Gemigliptin (prop.INN); SCHEMBL1262740; CHEMBL3707235; CHEBI:134731; ZINC68245464; AKOS025290873; PB11419; DB12412; API0013914; AK170799; 2-Piperidinone, 1-((2S)-2-amino-4-(5,8-dihydro-2,4-

Indication

Diabetic complication; ICD 11: 5A2Y; Status: Phase 3 [1]; Type-2 diabetes; ICD 11: 5A11; Status: Phase 3 [2]

• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

3 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Dapagliflozin + Gemigliptin	DCP5LVS	Dapagliflozin	Type 2 Diabetes Mellitus	[3]
Empagliflozin + Gemigliptin	DC7HT3V	Empagliflozin	Type 2 Diabetes Mellitus	[3]
Dapagliflozin + Gemigliptin	DC6U4RC	Dapagliflozin	Diabetes Mellitus, Type 2	[4]

References

• [1] ClinicalTrials.gov (NCT01990469) Efficacy and Safety of Gemigliptin 50mg qd Added in Patients With Type 2 Diabetes Inadequately Controlled on Glimepiride and Metformin. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] ClinicalTrials.gov (NCT03565458) Gemigliptin, Dapagliflozin, Empagliflozin DDI Study
• [4] ClinicalTrials.gov (NCT04255238) A Study to Evaluate the Efficacy and Safety of Dual add-on Therapy With Gemigliptin 50 mg and Dapagliflozin 10 mg Added to Metformin Who Have Inadequate Glycemic Control on Metformin Alone